Press & News

The next generation biopharmaceuticals

Press releases

2022-11-07

Affibody’s partner Rallybio Announces Positive Phase 1 Results for RLYB116

Solna, Sweden, November 7, 2022. Affibody’s licensee Rallybio Corporation, has announced positive topline results from a Phase 1 single ascending dose (SAD) study in healthy participants of RLYB116. • A single 100 mg subcutaneous dose demonstrated a reduction of >99% in free C5 and was generally well-tolerated. • Phase 1 Multiple...[read more]

Older press releases

2022-06-03

Affibody, ACELYRIN, and Inmagene Biopharmaceuticals Announce Data from Global Phase 2 Trial of Izokibep in Patients with Psoriatic Arthritis Presented During 2022 European Alliance of Associations for Rheumatology Congress

Data suggest efficacy over standard of care for the treatment of psoriatic arthritis Izokibep was well-tolerated, having a safety profile consistent with previous studies and the IL-17A inhibitor therapeutic class Supports hypothesis that izokibep offers greater efficacy with high...[read more]

2022-06-03

Affibody, ACELYRIN, and Inmagene Biopharmaceuticals Announce Data from Global Phase 2 Trial of Izokibep in Patients with Psoriatic Arthritis Presented During 2022 European Alliance of Associations for Rheumatology Congress

• Data suggest efficacy over standard of care for the treatment of psoriatic arthritis• Izokibep was well-tolerated, having a safety profile consistent with previous studies and the IL-17A inhibitor therapeutic class• Supports hypothesis that izokibep offers greater efficacy with...[read more]

2022-05-19

Report from Annual General Meeting in Affibody Medical AB (publ)

Solna, Sweden, May 19, 2022 – Affibody Medical AB (publ) today held its Annual General Meeting. The following resolutions were adopted. Adoption of the income statement and the balance sheet; allocation of result The Annual General Meeting adopted the...[read more]

Affibodys latest Press releases

2023-01-05

Positive Top-line Clinical Data for Izokibep in Hidradenitis Suppurativa

Solna, Sweden, January 5, 2023. Affibody’s partner ACELYRIN, Inc. today announced top-line 12-week open label data from a Phase...[read more]

Affibody in short

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

Upcoming reports Financial calendar

Interim Report January to March 2020 (May 15, 2020)
Interim Report January to June 2020 (August 21, 2020)
Interim Report January to September 2020 (November 13, 2020)
Year End Report 2020 (February 2021)

Investor information